Safety and Efficacy Study of IMSA101 in Refractory Malignancies
Status:
Recruiting
Trial end date:
2023-02-16
Target enrollment:
Participant gender:
Summary
Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients
receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor
(ICI) (Phase I and II)